This financing round was specifically structured as a win-win for both existing shareholders and the new investors. The proceeds will support ChemoTech's continued commercial growth, especially within the Animal Care segment, and help reinforce the company's trajectory toward cash-flow positive operations.

The new investors include:

-          Brothers Amitbir and Harbir Singh Banga with - 900,000 shares each with a total of 1,800,000 shares

-          Gayathri Kuppendra Reddy - 310,000 shares

Each investor has agreed to an 8-month lock-up period, highlighting their strong belief in ChemoTech's long-term vision and growth strategy. This commitment reflects a multi-year investment horizon and a shared confidence in the company's future potential.

The net proceeds will primarily support the Company's Animal Care operations, by strengthening its sales and marketing capacity, and act as buffer until achieving consistent cash-flow positive operations. The funds will also contribute to ongoing research and strategic market initiatives.

"This investment not only provides a valuable financial buffer in case of temporary fluctuations in revenue but also represents vital growth capital at a crucial stage in our journey," said Mohan Frick, CEO of ChemoTech. "Although structured as personal investments, it strengthens us significantly to welcome two new shareholders from strong entrepreneurial families who truly share our ambition to transform cancer care globally. They also share our ambition to scale our Animal Care business, VQ Animal Care Inc., to generate enough cash flow to finance our Human Care operations and potentially support new strategic investments in the near future. We are particularly excited about the strategic experience they bring-especially in Indian entrepreneurship, technology, network and the broader Indian market knowledge - all key success factors for succeeding in India."

Introduction of our new Investors

Mr. Amitbir Singh Banga is a forward-thinking entrepreneur with a strong industrial background and a proven track record in building operational excellence and sustainable growth. With a hands-on approach to leadership and innovation, he brings valuable experience from scaling complex businesses - qualities that align well with ChemoTech's mission and long-term strategy.

On behalf of the Banga family,
"We view Scandinavian ChemoTech as a highly promising company with significant market potential across both its Human and Animal Care. What truly drew us to this opportunity is that the company is not just working on promising ideas-it has already developed a proven and protected innovation in the form of its TSE technology, which is actively treating patients today.

We believe there are hundreds of thousands of patients globally-both human and animal-who could benefit from this technology immediately if made more widely available. Our ambition is to help accelerate that accessibility and play an active role in the journey to make TSE a standard of care in cancer treatment.

We also see strong synergies with our existing laparoscopic and MedTech investments, particularly when it comes to expanding in India and other emerging markets. In line with our long-term commitment, I intend to nominate myself for election to the Board of Directors at the upcoming General Meeting to support the company's continued growth in every way possible."
- Amritbir Singh Banga

Gayathri Kuppendra Reddy is a Bengaluru-based entrepreneur and climate advocate, leading ventures in sustainability, deep tech, and urban development. She is the founder of NOW Venture Studio and KReate Foundation and was named a Davos50 Young Leader by the World Economic Forum. She has also carried various leadership positions at RGA Infra Pvt Ltd, which is majority owned by her family's business RGA Software Systems.

"ChemoTech's patented technology platform represents a true breakthrough-one that has the potential to make advanced cancer care safer, faster, and significantly more affordable for patients in India and other emerging markets. I am investing because the team blends robust Swedish engineering with a strong mission to democratize access to quality oncology treatments-an ambition that deeply resonates with my commitment to driving industry-transformative solutions. I'm proud to support ChemoTech as it scales globally and delivers both meaningful impact and sustainable growth."

- Gayathri Kuppendra Reddy

For further information please contact:

Mohan Frick, CEO

Phone: +46 (0)10-218 93 00

E-mail: ir@chemotech.se

As of January 9th, 2025, we have discontinued translating our press releases into Swedish. Certain information will still be published in Swedish due to current regulations

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.